Clinical trials: ACT
Obesity
Learn, Engage, Act, Process (LEAP) for MOVE!
The overall goal of this project is to test whether the Learn. Engage. Act. Process (LEAP) intervention helps teams within the Veterans Health Administration's (VHA) local MOVE! group weight management programs be more in line…
- Trial name
- NCT02825680
- Testing
- Enhanced NCP Support, LEAP
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Healthy Participants
A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults
The purposes of this study are: To see how the new medicine (PF-06954522) under study behave. And if there are any important side effects. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take.
- Trial name
- NCT06003777
- Testing
- PF-06954522
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Uncomplicated Plasmodium Falciparum Malaria
Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria
The purpose of this study is to evaluate three dose levels of a combination tablet and a fixed dose granule formulation of pyronaridine and artesunate (PA) for the treatment of acute uncomplicated falciparum malaria in children.
- Trial name
- NCT00331136
- Testing
- Pyronaridine-Artesunate
- Where
- Gabon
- Volunteers
- 60 people
- Sponsor
- Medicines for Malaria Venture
Malaria, Vivax
Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria
Tafenoquine (TQ) is an 8-aminoquinoline anti-malarial drug which is in development as a single-dose treatment for the radical cure of P.vivax malaria when given with standard doses of chloroquine.
- Trial name
- NCT02802501
- Testing
- Tafenoquine, Primaquine, Dihydroartemisinin-piperaquine (DHA-PQP)
- Where
- Indonesia
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Hematopoietic Steam Cell Transplantation (HCT)
ACT to Reduce Morbidity and Mortality in Hematopoietic Stem Cell Transplant (HCT) Patients
This is a research study to develop and test a novel protocol to reduce physical and psychological vulnerabilities that contribute to treatment intolerance and treatment-related morbidity and mortality among hematopoietic stem…
- Trial name
- NCT04423939
- Testing
- Acceptance and Commitment Therapy (ACT)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Duke University
Breast Cancer
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004092
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- City of Hope Medical Center
Very Premature Baby
Attention Control Training (ACT) and Very Preterm Infants
Infants' attention control, defined as the ability to select what to pay attention to, is a fundamental building block for developing learning abilities and behaviour self-regulation.
- Trial name
- ACT (NCT03896490)
- Testing
- Attention Control Training, Control
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
Hypercholesterolemia
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
This non-interventional longitudinal study is a follow-up of the Austrian Cholesterol Screening and Treatment project (ACT I), which assessed the cholesterol status, including achievement of the target levels applicable at that…
- Trial name
- ACT II (NCT01381679)
- Testing
- Ezetimibe
- Volunteers
- 1,682 people
- Sponsor
- Organon and Co
Adolescent Behavior
I-ACT With Check Yourself
Adolescents have some of the highest rates of risk behaviors of all age groups and health behaviors developed in adolescence can persist into adulthood.
- Trial name
- NCT02764190
- Testing
- I-ACT with Check Yourself
- Where
- United States
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Seattle Children's Hospital
Malaria
Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients
The primary objective of this phase III study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) with that of Coartem® (artemether lumefantrine, AL) in children and adults…
- Trial name
- NCT00422084
- Testing
- Pyronaridine artesunate, Coartem® (artemether lumefantrine)
- Where
- 10 sites in Democratic Republic of the Congo, Ghana and 7 more
- Volunteers
- 1,272 people
- Sponsor
- Medicines for Malaria Venture
Migraine, Depression
Brief Behavioral Intervention for Comorbid Migraine and Depression
The purpose of this research study is to examine whether a one-day group workshop, integrating principles from Acceptance and Commitment Therapy with Migraine Education, will result in improvements in depressive symptoms and…
- Trial name
- ACT-IM (NCT01775852)
- Testing
- ACT-IM
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Lilian N. Dindo
Contraception, Sexually Transmitted Infections
Connecting Healthy Women: Examining the Effect of an Intervention From the Effect of Being Reachable
The investigators propose to test a community-developed and targeted intervention that employs community health workers (CHWs) as aides to newly Medicaid-insured women.
- Conditions
- Contraception, Sexually Transmitted Infections, Cervical Cancer
- Trial name
- NCT02157168
- Testing
- Community health worker
- Where
- United States
- Volunteers
- 2,267 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Coronary Artery Disease
Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol (Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide (Ultravist® 370) and iomeprol (Iomeron® 400)…
- Trial name
- X-ACT (NCT01255722)
- Testing
- iobitridol, iopromide, iomeprol
- Where
- 23 sites in France, Germany and 3 more
- Volunteers
- 468 people
- Sponsor
- Guerbet